Distinguished in Neuroendocrine Tumor

Marta Benavent

Sevilla, AN, ES 
Distinguished in Neuroendocrine Tumor
Sevilla, AN, ES 
OverviewLocationsClinical Research

Overview

Marta Benavent practices in Sevilla, Spain. Ms. Benavent is rated as a Distinguished expert by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, Embryonal Tumor with Multilayered Rosettes, Carcinoid Syndrome, and Appendectomy.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 17 articles and participated in 6 clinical trials in the study of Neuroendocrine Tumor.

Gender
Female

Locations

Sevilla, AN, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Surufatinib
Study Phase: Phase 2
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Unknown
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Enrollment Status: Completed
Publish Date: March 24, 2020
Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.
Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.
Enrollment Status: Completed
Publish Date: March 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

24 Total Publications

Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Benavent's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile